Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia
Open Access
- 15 November 2007
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 110 (10) , 3532-3539
- https://doi.org/10.1182/blood-2007-05-091942
Abstract
The primary objective was to describe the prevalence and characteristics of microbiologically defined infections and infection-related mortality (IRM) in 492 children with acute myeloid leukemia enrolled on CCG 2961. Secondary objectives were to determine the relationship between demographic, disease-related, and therapeutic variables, and infections and IRM. Institutions documented infections prospectively. Age, ethnicity, body mass index, leukemia karyotype, treatment, and institutional size were examined for association with infection outcomes. More than 60% of children experienced such infections in each of 3 phases of chemotherapy. There were 58 infectious deaths; cumulative incidence of IRM was 11% plus or minus 2%. Thirty-one percent of infectious deaths were associated with Aspergillus, 25.9% with Candida, and 15.5% with alpha hemolytic streptococci. Age older than 16 years (hazard ratio [HR], 3.32; 95% confidence interval [CI], 1.87-5.89; P < .001), nonwhite ethnicity (HR, 1.85; 95% CI, 1.10-3.09; P = .02), and underweight status (HR, 3.06; 95% CI, 1.51-6.22; P = .002) were associated with IRM, while size of the treating institution was not. Thus, age, ethnicity, and BMI were important contributors to IRM. Fungi and Gram-positive cocci were the most common organisms associated with IRM and, in particular, Aspergillus species was the largest contributor to infectious deaths.Keywords
This publication has 12 references indexed in Scilit:
- Low incidence of sepsis due to viridans streptococci in a ten‐year retrospective study of pediatric acute myeloid leukemiaPediatric Blood & Cancer, 2005
- Mortality in Overweight and Underweight Children With Acute Myeloid LeukemiaJAMA, 2005
- Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93Leukemia, 2003
- Centers for Disease Control and Prevention 2000 Growth Charts for the United States: Improvements to the 1977 National Center for Health Statistics VersionPediatrics, 2002
- Treatment‐related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council Acute Myeloid Leukaemia Trial (MRC AML10)British Journal of Haematology, 1999
- Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trialBritish Journal of Haematology, 1998
- High Dose Cytosine Arabinoside is a Major Risk Factor for the Development of Hepatosplenic Candidiasis in Patients with LeukemiaLeukemia & Lymphoma, 1997
- High-Dose Cytosine Arabinoside and Viridans Streptococcus Sepsis in Children with LeukemiaPediatric Hematology and Oncology, 1995
- Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 casesInfection, 1990
- High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemiaJournal of Molecular Medicine, 1987